Expression of PAFR as Part of a Prosurvival Response to Chemotherapy: A Novel Target for Combination Therapy in Melanoma
Figure 3
Combination therapy using cisplatin and the antagonist of PAFR is more efficient than either therapy alone (a) Average tumour volume in each experimental group (±SEM) measured daily. (b) Percentage of complete tumour regression in each experimental condition.
